User:Logan4321/sandbox

you can make coke with thease steps The Coca-Cola Company's formula for Coca-Cola syrup, which bottlers combine with carbonated water to create the company's flagship cola soft drink, is a closely guarded trade secret. Company founder Asa Candler initiated the veil of secrecy that surrounds the formula in 1891 as a publicity, marketing, and intellectual property protection strategy. While several recipes, each purporting to be the authentic formula, have been published, the company maintains that the actual formula remains a secret, known only to a very few select (and anonymous) employees.

Contents 1	History 2	Current ingredients 3	Formula variations in the United States 3.1	Passover 3.2	"New Coke" 3.3	Mexican Coke 4	Purported secret recipes 4.1	Pemberton recipe 4.2	Merory recipe 4.3	Beal recipe 5	Commercial teaser 6	See also 7	References 8	External links crona update This article is about ongoing research for potential COVID-19 vaccines. For potential therapeutic drugs for COVID-19, see COVID-19 drug development. For drugs that may be repurposed for treating COVID-19, see COVID-19 drug repurposing research. Part of a series on the COVID-19 pandemic SARS-CoV-2 without background.png SARS-CoV-2 (virus)COVID-19 (disease) Timeline Locations International response Medical response Disease testingVaccine research Drug developmentDrug repurposing Impact SARS-CoV-2 (Wikimedia colors).svg COVID-19 Portal vte A COVID‑19 vaccine is any of several different vaccine technologies intended to provide acquired immunity against coronavirus disease 2019 (COVID‑19).[1] Previous work to develop a vaccine against the coronavirus diseases SARS and MERS established knowledge about the structure and function of coronaviruses, which accelerated development during early 2020 of varied technology platforms for a COVID‑19 vaccine.[2]

As of December 2020, 59 vaccine candidates were in clinical research: namely 42 in Phase I–II trials and 17 in Phase II–III trials.[3][4][5][6] No vaccine candidate has yet fully completed a Phase III trial.

In November 2020, Pfizer Inc and BioNTech,[7] Moderna[8] and the University of Oxford (in collaboration with AstraZeneca),[9][10] announced positive results from interim analyses of their Phase III vaccine trials. On 2 December, temporary regulatory approval was granted by the UK medicines regulator MHRA for the Pfizer-BioNTech vaccine,[11] which is also under evaluation for emergency use authorization (EUA) status by the US FDA, and in several other countries.[12]

The World Health Organization (WHO), the Coalition for Epidemic Preparedness Innovations (CEPI), and the Gates Foundation (GF) are committing money and organizational resources for the prospect that several vaccines will be needed to prevent continuing COVID‑19 infection.[13] The CEPI, which is organizing a US$2 billion worldwide fund for rapid investment and development of vaccine candidates,[14] indicated in September that clinical data to support licensure may be available by the end of 2020.[3] On 4 May 2020, the WHO organized a telethon which received US$8.1 billion in pledges from forty countries to support rapid development of vaccines to prevent COVID‑19 infections.[15] At the same time, the WHO also announced the deployment of an international "Solidarity trial" for simultaneous evaluation of several vaccine candidates reaching Phase II–III clinical trials.[16]